{"id":24048,"date":"2021-01-15T11:38:34","date_gmt":"2021-01-15T10:38:34","guid":{"rendered":"https:\/\/php8.plastv.de\/?p=24048"},"modified":"2021-01-15T11:38:34","modified_gmt":"2021-01-15T10:38:34","slug":"durect-announces-closing-of-lactel-sale-to-evonik","status":"publish","type":"post","link":"https:\/\/plas.tv\/?p=24048","title":{"rendered":"DURECT Announces Closing of LACTEL Sale to Evonik"},"content":{"rendered":"
\n
\n

DURECT Corporation Announces Closing of LACTEL\u00ae Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million<\/h3>\n<\/div>\n<\/div>\n
\n
\n

DURECT Corporation<\/a> (Nasdaq: DRRX) has announced that the sale of the LACTEL product line to Evonik closed and the $15 million payment was received on December 31, 2020.<\/p>\n

About\u00a0DURECT Corporation
\n<\/b>DURECT\u00a0is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company’s lead drug candidate is in clinical development forDURECT Corporation Announces Closing of LACTEL\u00ae Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation, COVID-19 patients with acute liver or kidney injury, and non-alcoholic steatohepatitis (NASH). DURECT’s proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR\u00ae (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. For more information about DURECT, please visit www.durect.com<\/a>\u00a0and follow us on Twitter\u00a0https:\/\/twitter.com\/DURECTCorp<\/a>.<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

DURECT\u00a0is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases…<\/p>\n","protected":false},"author":2,"featured_media":7007,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24,16],"tags":[],"series":[],"class_list":["post-24048","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-plas-tv-meldungen-auf-der-startseite-unterhalb-slider","category-plast-tv-textmeldungen"],"_links":{"self":[{"href":"https:\/\/plas.tv\/index.php?rest_route=\/wp\/v2\/posts\/24048","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/plas.tv\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/plas.tv\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/plas.tv\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/plas.tv\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24048"}],"version-history":[{"count":1,"href":"https:\/\/plas.tv\/index.php?rest_route=\/wp\/v2\/posts\/24048\/revisions"}],"predecessor-version":[{"id":24049,"href":"https:\/\/plas.tv\/index.php?rest_route=\/wp\/v2\/posts\/24048\/revisions\/24049"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/plas.tv\/index.php?rest_route=\/wp\/v2\/media\/7007"}],"wp:attachment":[{"href":"https:\/\/plas.tv\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24048"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/plas.tv\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24048"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/plas.tv\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24048"},{"taxonomy":"series","embeddable":true,"href":"https:\/\/plas.tv\/index.php?rest_route=%2Fwp%2Fv2%2Fseries&post=24048"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}